Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$75,000.00

The impact of gut microbiota on the tumor microenvironment, response to neoadjuvant treatment and survival in patients with colorectal cancer

EF 2024-25

Résumé
Colorectal cancer is a major public health issue in Canada. To cure this cancer, surgery is usually performed to remove the diseased segment of the bowel. In advanced colon and rectal cancer , surgery is associated with high risks of complications. Patients therefore receive treatments of chemotherapy and radiotherapy to decrease the size of the tumor before surgery. In some patients, the tumor responds completely to these treatments, and sometimes disappear. In these cases, surgery is not necessary. This unpredictable event is not well understood, and it is still impossible to know which patients will respond well and which patients will not. The gut microbiota, or the collection of bacteria in the gut, has been shown to influence cancer development and major functions of the immune system. Our team and others have shown that some bacteria present in the bowel may promote the healing of the bowel after surgery, intestinal inflammation and cancer recurrence. In this project, our hypothesis is that the gut microbiome may influence the response of colorectal cancer to chemotherapy and radiotherapy. To assess this link, we will compare the gut microbiota of responders and non-responders to these therapies. Fecal, tumor and blood samples will be collected from patients with colorectal cancer. The fecal and tumor microbiome, and the metabolome, or the collection of molecules and metabolites produced by gut bacteria, will be analyzed to detect differences before these treatments are initiated. Markers of the immune system will be also compared to assess for potential differences. Candidate bacteria that are potentially involved in the response to treatment will be isolated and investigated in the laboratory to better understand their mechanism of action. Findings from this project may potentially lead to major changes in clinical practice, and may prevent patients from undergoing invasive surgical procedures while improving their survival.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Minnesota, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
513547
Name
Hajjar Roy
Region
Minnesota
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
The impact of gut microbiota on the tumor microenvironment, response to neoadjuvant treatment and survival in patients with colorectal cancer
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$75,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Colorectal Cancer; Gut Barrier; Gut Microbiome; Tumor Microenvironment
Abstract
Colorectal cancer is a major public health issue in Canada. To cure this cancer, surgery is usually performed to remove the diseased segment of the bowel. In advanced colon and rectal cancer , surgery is associated with high risks of complications. Patients therefore receive treatments of chemotherapy and radiotherapy to decrease the size of the tumor before surgery. In some patients, the tumor responds completely to these treatments, and sometimes disappear. In these cases, surgery is not necessary. This unpredictable event is not well understood, and it is still impossible to know which patients will respond well and which patients will not. The gut microbiota, or the collection of bacteria in the gut, has been shown to influence cancer development and major functions of the immune system. Our team and others have shown that some bacteria present in the bowel may promote the healing of the bowel after surgery, intestinal inflammation and cancer recurrence. In this project, our hypothesis is that the gut microbiome may influence the response of colorectal cancer to chemotherapy and radiotherapy. To assess this link, we will compare the gut microbiota of responders and non-responders to these therapies. Fecal, tumor and blood samples will be collected from patients with colorectal cancer. The fecal and tumor microbiome, and the metabolome, or the collection of molecules and metabolites produced by gut bacteria, will be analyzed to detect differences before these treatments are initiated. Markers of the immune system will be also compared to assess for potential differences. Candidate bacteria that are potentially involved in the response to treatment will be isolated and investigated in the laboratory to better understand their mechanism of action. Findings from this project may potentially lead to major changes in clinical practice, and may prevent patients from undergoing invasive surgical procedures while improving their survival.
Competitiondate
202410
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hajjar, Roy
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $75,000~ $0~